Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229900 · ClinicalTrials.gov registry record · Phase 1
A Study of SGN-ALPV in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT05229900 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 43 participants.
The verdict
NCT05229900, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.
Interventions
- DRUG SGN-ALPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05229900
The ClinicalTrials.gov registry entry for NCT05229900 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-ALPV is the first listed.
NCT05229900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05229900 about?
NCT05229900 is a clinical study titled "A Study of SGN-ALPV in Advanced Solid Tumors". This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body...
What is the current status of trial NCT05229900?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-04-21. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT05229900?
The interventions under investigation include: SGN-ALPV (DRUG).
Who is sponsoring clinical trial NCT05229900?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.